MedReleaf posted the company’s third quarter financials this morning. The numbers speak for themselves.
- Sold 1,263 kilograms of cannabis products an increase of 27% from the prior year period
- Total sales of $11.4 million, an increase of 9% from the prior year period
- At the end of December 31, 2017, the Company had cash and cash equivalents of $114.6 million, working capital of $137.9 million.
Third Quarter Fiscal 2018 Financial Summary
|
Three Months |
||||
|
December 31, |
||||
|
CAD$ (in 000s, except grams sold) |
2017 |
2016 |
||
|
Dried Cannabis |
8,573 |
9,831 |
||
|
Extracts |
2,349 |
296 |
||
|
Other |
428 |
299 |
||
|
Total Sales |
11,350 |
10,426 |
||
|
Gross Profit |
9,985 |
9,714 |
||
|
Adjusted Product Contribution Margin* |
7,330 |
8,594 |
||
|
Adjusted EBITDA* |
(233) |
4,093 |
||
|
Net Income (loss) |
(5,001) |
1,738 |
||
|
Net Income (loss) per share – diluted |
$(0.05) |
$0.02 |
||
|
Total grams sold* |
1,263,490 |
993,259 |
||
|
Average selling price per gram – Dried Cannabis |
$8.05 |
$10.41 |
||
|
Average selling price per gram – Extracts |
$11.83 |
$6.11 |
||
|
Total average selling price per gram |
$8.98 |
$10.50 |
||
|
Adjusted product contribution per gram sold* |
$5.80 |
$8.65 |
||
|
Cash cost per gram sold* |
$1.83 |
$1.55 |
||
|
*Non-IFRS Measures |
||||
